**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 53975

**Manuscript Type:** REVIEW

**Isoflavones and inflammatory bowel disease**

Wu ZY *et al*. Isoflavones and IBD

Ze-Yu Wu, Li-Xuan Sang, Bing Chang

**Ze-Yu Wu**, **Bing Chang,** Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Li-Xuan Sang,** Department of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Author contributions:** Wu ZY wrote the manuscript; Sang LX and Chang B participated in the critical revision of the manuscript; all the authors approved the final manuscript.

**Supported by** Innovative Talent Support Program of the Institution of Higher Learning in Liaoning Province, No. 2018-478; and Innovative Talents of Science and Technology Support Program of Young and Middle People of Shenyang, No. RC170446.

**Corresponding author: Bing Chang, PhD, Associate Professor, Chief Doctor,** Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. cb000216@163.com

**Received:** January 2, 2020

**Revised:** March 27, 2020

**Accepted:** April 24, 2020

**Published online:**

**Abstract**

Isoflavones constitute a class of plant hormones including genistein, daidzein, glycitein, formononetin, biochanin A, and irilone, and the major source of human intake is soybeans. Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease including ulcerative colitis, Crohn’s disease, and indeterminate colitis, which seriously affects the quality of life of patients and has become a global health problem. Although the pathogenesis of IBD is not very clear, many factors are thought to be related to the occurrence and development of IBD such as genes, immunity, and intestinal flora. How to control IBD effectively for a long time is still a problem for gastroenterologists. Diet has an important effect on IBD. Patients with IBD should pay more attention to diet. To date, many studies have reported that isoflavones have both good and bad effects on IBD. Isoflavones have many activities such as regulating the inflammatory signal pathways and affecting intestinal barrier functions and gut flora. They can also act through estrogen receptors, as they have a similar structure to estrogen. Isoflavones are easy to get from diet for human. Whether they are valuable to be applied to the treatment of IBD is worth studying. This review summarizes the relationship between isoflavones and IBD.

**Key words:** Isoflavone; Metabolism; Effects; Inflammatory bowel disease; Structure; Treatment

Wu ZY, Sang LX, Chang B. Isoflavones and inflammatory bowel disease. *World J Clin Cases* 2020; In press

**Core tip:** Isoflavones constitute a class of plant hormones, and the major source of human intake is soybeans. Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease, which seriously affects the quality of life of patients. To date, many studies have reported that isoflavones have effects on IBD. Isoflavones have many activities, such as regulating the inflammatory signal pathways, intestinal barrier function, and gut flora. They can also act through estrogen receptors, because they have a similar structure to estrogen. This review summarizes the relationship between isoflavones and IBD.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease. There are three forms of IBD: Ulcerative colitis (UC), Crohn’s disease (CD), and indeterminate colitis[1,2]. The etiology is not very clear, and this disease has a close relationship with genes, immunity, intestinal flora, *etc*[3]. The incidence of IBD is increasing[4,5]. IBD has become a global health problem[6]. Studies found that diet can affect the intestinal flora of the human body and then affect human immunity[7-9]. Therefore, diet plays an important role in the occurrence and development of IBD.

A Westernized diet can promote the occurrence and development of IBD[10]. A large intake of total fats, polyunsaturated fatty acids, meat, and omega-6 fatty acids increased the risk of UC and CD, while a high intake of dietary fiber, fruits, and vegetables can reduce the risk[11]. Some foods, such as omega-3 fatty acid-rich fish, monounsaturated fat, fruits, and vegetables, are recommended as part of the diet of IBD patients[7]. The Asian population has its own dietary structure and soy products are an integral part, thus the intake of isoflavones in Asians is high[12]. Isoflavones are a class of phytoestrogens, the structure of which is similar to that of estrogen[13], and they were reported to have effects on many diseases, including osteoporosis[14], cardiovascular disease[15], breast cancer[16], colorectal cancer[17], and Alzheimer’s disease[18]. In recent years, studies have reported the effect of isoflavones on IBD. In this paper, we review the relationship between isoflavones and IBD.

**ISOFLAVONE**

Isoflavones constitute a class of phytoestrogens, which include genistein, daidzein, glycitein, formononetin, biochanin A, and irilone. The first three are from soybeans, and the last three are from red clover[13,19]. The content of isoflavones is the most abundant in soybeans and their derivatives, which are the major source of isoflavones for humans. In addition, the content of isoflavones in different derivatives is related to the processing methods of soybeans[20,21]. There are two forms of isoflavones: Glucosides and aglycones[13,22], which are absorbed in the human body in both the small and large intestine[23]. Isoflavones in the form of aglycones are absorbed faster than glucosides, which can be hydrolyzed into bioactive aglycones in the proximal intestine for better absorption[24,25]. Isoflavones are mainly in the form of glucuronide in human blood, accounting for 75%; 24% in the form of sulfate; and ≤ 1% in the form of aglycone[26]. Isoflavones are similar to estrogen in structure, thus, isoflavones can bind to estrogen receptors[27].

**METABOLISM OF ISOFLAVONES IN THE INTESTINE**

Isoflavones can be metabolized into equol and O-demethylangolensin（O-DMA）[28]. The metabolism for these is different in different individuals. In China, Korea, and Japan, more than 80% of the population can produce equol, while only 25% of the population in North America and Europe can produce it[25]. There are a large number of intestinal floras that play an important role in metabolism. Many intestinal floras can metabolize isoflavones. Some lactic acid bacteria and bifidobacteria with β-glucosidase activity can transform glycoside into aglycone isoflavone[29]. Lactic acid bacteria and bifidobacteria prefer to transform genistin into genistein[30]. However, not all isoflavones can be metabolized by intestinal floras. Irilone, a red clover isoflavone, is difficult for intestinal bacteria to degrade[19].

*Eubacterium limosum* is an absolute anaerobic bacterium in the human intestinal tract, which was shown to O-demethylate isoflavones and convert biochanin A, formononetin, and glycitein into genistein, daidzein, and 6,7,4’-trihydroxyisoflavone, respectively, but it could not further transform these three products[31]. *Bifidobacterium* was demonstrated to convert daidzin into daidzein, but not into equol[32]. *Escherichia coli* HGH21 and a Gram-positive (G+) strain HGH6 transformed daidzin and genistin into daidzein and genistein, respectively[33]. *Clostridium sp. strain* HGH 136, a G+ anaerobic bacterium in the gut, transformed daidzein into O-DMA by cutting off the C-ring of isoflavones[34]. *Eubacterium ramulus* also converted daidzein to O-DMA[35]. Strain SY8519, a strain belonging to *Clostridium* rRNAclusterXIVa in the human intestine, produced O-DMA from daidzein[36].

Some intestinal microfloras were shown to convert daidzein and genistein into dihydrodaidzein and dihydrogenistein, two intermediate metabolites, respectively[29,37]. Tamura *et al*[38] isolated a *Clostridium*-like bacterial strain, TM-40, from the feces of a 7-year-old boy. It could transform isoflavones both daidzein and daidzin into dihydrodaidzein but did not produce equol. The strain was 93% similar to *Coprobacillus catenaformis*[38]. *Enterococcus faecalis* INIA P333 and *Lactobacillus rhamnosus* INIA P540 converted daidzein into DHD[29]. In an anaerobic environment, the G+ strain HGH6 further converted daidzein and genistein into dihydrodaidzein and dihydrogenistein, respectively, but HGH6 could not further convert dihydrodaidzein and dihydrogenistein[33].

Certain bacteria can convert isoflavones into equol. The rod-shaped Gram-negative bacterium, *Eggerthella* strain Julong 732, in the human intestine, was demonstrated to transform dihydrodaidzein into S-equol in an anaerobic environment. Full 16S RNA gene sequence analysis indicated that the bacterium was 92.8% similar to *Eggerthella hongkongenis* HKU10[39,40]. *Eggerthella sp.* YY7918, a bacterium that is 93.3% similar to *Eggerthella hongkongenis* HKU10, also converted daidzein and dihydrodaidzein into equol[41]. *Slackia isoflavoniconvertens* converted daidzein into equol and genistein into 5-hydroxy-equol[42]. *Slackia equolifaciens sp.* *nov., Slackia sp.* strain NATTS, and *Lactococcus* strain 20-92 converted daidzein into equol[43-45]. The metabolic process of isoflavones is shown in Figure 1.

**CHANGES IN IBD**

UC and CD are the two main forms of IBD. UC can affect the end of the ileocecum, the whole colon, and rectum, and CD can affect the whole digestive tract, which seriously affects the quality of life for patients. The changes of IBD can occur in the intestinal mucosal barrier, the intestinal flora, and their metabolites, cytokines.

The intestinal barrier of IBD patients is abnormal, and the mucous layer and epithelial cells of the intestinal tract are changed. Mucin 2 and IgG Fc-binding protein, the main components of the mucus layer of intestinal barrier, decrease in the active UC, leading to a thinning of the mucus layer. This change occurs in the early stage of UC, even before the inflammation[46,47]. Intestinal mucosal barrier damage and increased intestinal mucosal permeability are associated with the occurrence of UC and CD[48] and abnormal intestinal tight junctions are one of mechanisms leading to these changes[49].

There are abnormalities in the cytokines of IBD patients. For example, studies found that interleukin (IL)-17A and IL-23 were increased in IBD patients, and they were increased more in UC than in CD[50]. Lena Öhman *et al*[51] found that the level of serum IL-17A was related to the severity of newly diagnosed, untreated UC. Cytokines, such as the IL-1 family and IL-17, play an important role in the development of IBD[52].

An imbalance of intestinal flora is closely related to the incidence of IBD. The abundance, evenness, and diversity of intestinal flora in UC patients are reduced[53]. Some gut microfloras that are very important for maintaining intestinal homeostasis show dysbiosis, such as the butyrate-producing microflora, human *Roseburia hominis*, and *Faecalibacterium prausnitzii* (*F. prausnitzii*), which are reduced in UC patients[54]. Even in the first-degree relatives of UC patients, *F. prausnitzii* is decreased[55]. In addition to UC patients, healthy people living with UC patients also have certain intestinal dysbiosis[56]. The dysbiosis in CD is more serious than that in UC[57], mainly causing a reduction of the phylum Firmicutes[58]. The dysbiosis of viruses and fungi also plays a role in the development of IBD[59,60].

An imbalance of metabolites, caused by the imbalance of intestinal flora, also affects the occurrence and development of IBD. Short-chain fatty acids (SCFAs), including acetic acid, propionic acid, and butyric acid, are produced by intestinal microflora and play an important role in the intestinal tract[61]. SCFAs were reported to promote the production of IL-10, an anti-inflammatory cytokine, by Th1 cells and to have anti-inflammatory effects[61,62]. In a colitis mouse model, it was found that butyrate, an SCFA, can maintain the balance of Th17/Treg in the intestinal tract and has an anti-inflammatory effect[63]. A decrease of SCFA can also increase the intestinal permeability[64]. Therefore, the regulation of intestinal microflora and its metabolites is of great significance to the recovery of IBD.

**ISOFLAVONE AND IBD**

In recent years, studies have reported the effects of isoflavones on IBD. In a mouse model, daidzein and glyceolins (isopentehexene isoflavone, a derivative of daidzein, produced by soybeans under stress), relieved dextran sulfate sodium (DSS)-induced colitis, therefore, they may be used in the treatment of UC[65,66]. A moderate isoflavone intake by UC patients in the remission period was beneficial[67]. Isoflavones demonstrated effects on the symptoms of UC patients in the remission period. Isoflavones intake may contribute to reducing the incidence of abdominal pain[67]. A high intake of daidzein and total isoflavones helped to reduce the mucus in the feces of UC patients; however, a high intake of daidzein alone may increase fecal pus[68]. It was reported that soybean isoflavones may have a preventive effect on CD[69].

Isoflavones have an anti-inflammatory effect[70]. After treatment with genistein, an isoflavone, inflammation was reduced in a 2,4,6-trinitrobenzenesulfonic acid-induced colitis rat model[71]. Isoflavones play a role in many aspects of inflammation. The expression and activation of the signal translator and activator of transcription 1 increased in the intestines of patients with IBD[72]. Daidzein and genistein were shown to inhibit signal translator and activator of transcription 1 and then to reduce the expression of inducible nitric oxide synthase (iNOS)[73]. The overproduction of NO caused by the induction of iNOS could lead to massive prostaglandin E2 (PGE2) production through cyclooxygenase-2 S-nitrosylation[74]. PGE2 has a proinflammatory effect[75] and massive PGE2 could damage the intestinal integrity[76].

Isoflavones were shown to inhibit the tumor necrosis factor α (TNF-α) induced production of chemokine IL-8 by Caco-2 cells[77], reduce the inflammatory cell infiltration in the intestines, decrease the level of myeloperoxidase, inhibit the nuclear factor-κB (NF-κB) pathway and the expression of inflammatory factors (such as IL-6, IL-1 β, and TNF-α), and reduce the levels of NO and PGE2 in colonic tissues[65].

NF-κB is a family of transcription factors, including RelA (p65), c-Rel, RelB, p105/p50, and p100/p52[78], and almost all cells in the human body can express NF-κB[79]. The activity of NF-κB is controlled by the inhibitory κB protein and the inhibitory κB protein kinase.There are two ways to activate NF-κB. One is the classical way: Bacterial products and proinflammatory factors, such as TNF-α and IL-1, can phosphorylate and degrade IκB α and activate p65/p50 through the IκB kinase (IKK) complex. Another is the nonclassical pathway: The TNF cytokine family, additional to TNF-α, can phosphorylate p100 and activate p52/RelB through the IKK complex[79,80]. The NF-κB signaling pathway plays a dual role in the gut[81]. On the one hand, the activation of NF-κB induces the expression of chemokines, cytokines, and adhesion factors to promote the development of inflammation[78]. On the other hand, NF-κB is important in maintaining the integrity of the intestinal mucosal barrier and intestinal mucosal homeostasis[82].

Daidzein reduced the secretion of pro-inflammatory factors by inhibiting the NF-κB signaling pathway[65]. Kim *et al*[83] found that soybean isoflavones inhibited the activation of macrophages by inhibiting the phosphorylation of the IκB protein and the degradation of IKK in a DSS-induced colitis mouse model. M1 macrophages damaged the intestinal epithelial cell barrier through TNF-α[84]; however, genistein promoted the transformation of M1 macrophages into M2, reduced cytokines, and reduced T cells in the lamina propria of the colon[85]. It was reported that soybean isoflavones may reduce DSS-induced intestinal inflammation by inhibiting the TLR4/MyD88 signal[86]. Stimuli in the intestinal tract could activate NF-κB through TLR4/MyD88[78].

In addition, isoflavones can inhibit the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Abnormal activation of the NLRP3 inflammasome may be an important mechanism of IBD occurrence and development. The NF-κB pathway could induce the expression of the NLRP3 inflammasome[87]. Bauer *et al* used DSS to induce colitis in mice and found that the NLRP3 inflammasome played an important role in the development of intestinal inflammation. DSS activated caspase-1 through NLRP3 inflammasome and transformed IL-1β and IL-18 into their active forms[88]. IL-1β and IL-18 are important pro-inflammatory cytokines[89], and IL-1β can increase intestinal tight junction permeability through the classical NF-κB pathway[90,91].

However, the effect of IL-18 on the intestinal mucosal barrier is controversial[92,93]. Both a protective effect and a destructive effect have been reported. Genistein inhibited the NLRP3 inflammasome in macrophages through the G-protein-coupled bile acid receptor 1, also known as TGR5[94]. However, Hirota *et al*[95] found that, in mice that had lost the NLRP3 inflammasome, experimental colitis was likely to appear. A lack of the NLRP3 inflammasome can damage the intestinal barrier function and cause inflammation, which may be related to promoting epithelial cell apoptosis and reducing epithelial cell proliferation[96].

IL-17 also plays an important role in IBD. IL-17A and IL-17C can regulate occludin and maintain the integrity of the barrier[97,98]. Inhibiting IL-17 weakens the barrier function of intestinal epithelial cells. Therefore, anti-IL-17A treatment will aggravate IBD[99,100]. Isoflavones increased the gene expression of *IL-17A* in immune cells[101]. Biochanin A activated *IL-17* transcription, which is dependent on retinoic acid receptor-related orphan receptor γ[102]. However, IL-17 by itself could gather inflammatory cells and promote the development of inflammation in coordination with other cytokines[103], and IL-17 increased in the serum and intestinal mucosa of IBD patients[104]. As a result, the up-regulation of IL-17 by isoflavones may play a role in promoting the development of IBD.

The estrogen-like effect of isoflavones also has an effect on IBD. Estrogen was found to alleviate endoplasmic reticulum stress, reduce the production of pro-inflammatory factors through epithelial cells, and improve the barrier function of intestinal epithelial cells (by up-regulating the tight junction proteins)[105]. The colon estrogen β receptor signaling pathway up-regulated the expression of occludin and the junctional adhesion molecule A in epithelial cells and reduced the intestinal permeability[106]. Therefore, the estrogen-like effect of soybean isoflavones could improve the gut barrier function[107].

Soybean isoflavones can also regulate the intestinal flora. Genistein reduced the growth rate of *Lactococcus lactis subsp. lactis*, *Slackia equolifaciens*, and *Bacteroides fragilis*, while genistein and equol increased the growth rate of *F. prausnitzii* and *Lactobacillus rhamnosus*[108]. *Lactobacillus rhamnosus* GG had an anti-inflammatory effect both *in vivo* and *in vitro*[109], and *Lactobacillus rhamnosus* CNCM I-3690 had a protective effect on the intestinal barrier[110]. *F. prausnitzii* is a flora in the human intestinal tract, which was shown to produce butyrate and play an anti-inflammatory role by regulating the balance of Th17/Treg in the intestinal tract. Butyrate is a kind of SCFA, which is very important for intestinal health. Isoflavone could increase butyrate and acetate[63,111]. In addition, isoflavones promoted the production of SCFA *in vitro*[112]. Therefore, isoflavones can increase intestinal SCFA, and SCFA can further promote the growth of flora that can produce butyrate, have an anti-inflammatory effect, and protect the intestinal barrier function. This may form a virtuous cycle and finally promote the recovery of IBD.

However, different opinions have been expressed in certain studies. An increased intake of isoflavones increased the risk of UC, especially in the female population[113]. Moreover, the early adoption of an isoflavone-rich diet did not avoid the occurrence and development of IBD in a rat model[114]. This may be related to the estrogen effect of isoflavones. The effect of estrogen on IBD has been reported. One study found that postmenopausal women who take estrogen or progesterone supplements had an increased risk of UC[115], and another study also found that patients who take oral contraceptives had an increased risk of IBD[116]. The effects of isoflavones on IBD are shown in Figure 2.

**CONCLUSION**

The incidence of IBD is increasing worldwide. The quality of life of IBD patients is seriously impacted and IBD cannot be cured at present. How to control IBD effectively for a long time is, therefore, of particular importance. Isoflavones have certain therapeutic effects on IBD through inhibiting inflammation, as well as regulating intestinal flora and its metabolites. Therefore, isoflavones may have a certain potential in the treatment of IBD. However, the two-way effect of the NLRP3 inflammasome and IL-17 would lead to a dual effect of isoflavones on IBD. The effects of isoflavones may be related to the dosage, frequency of use, intestinal flora, and the type and severity of IBD. Therefore, we suggest that future research should focus on the dosage and frequency of use of isoflavones in relation to their positive effects and compare the disease characteristics and intestinal flora characteristics of people with different effects, so as to determine how to take advantage of the beneficial role of isoflavones for IBD.

**REFERENCES**

1 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

2 **Guindi M**, Riddell RH. Indeterminate colitis. *J Clin Pathol* 2004; **57**: 1233-1244 [PMID: 15563659 DOI: 10.1136/jcp.2003.015214]

3 **Loddo I**, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. *Front Immunol* 2015; **6**: 551 [PMID: 26579126 DOI: 10.3389/fimmu.2015.00551]

4 **Kaplan GG**. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 720-727 [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150]

5 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

6 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2018; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

7 **Kakodkar S**, Mutlu EA. Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease. *Gastroenterol Clin North Am* 2017; **46**: 745-767 [PMID: 29173519 DOI: 10.1016/j.gtc.2017.08.016]

8 **Turnbaugh PJ**, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* 2009; **1**: 6ra14 [PMID: 20368178 DOI: 10.1126/scitranslmed.3000322]

9 **De Filippo C**, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* 2010; **107**: 14691-14696 [PMID: 20679230 DOI: 10.1073/pnas.1005963107]

10 **Chiba M**, Nakane K, Komatsu M. Westernized Diet is the Most Ubiquitous Environmental Factor in Inflammatory Bowel Disease. *Perm J* 2019; **23**: 18-107 [PMID: 30624192 DOI: 10.7812/TPP/18-107]

11 **Hou JK**, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol* 2011; **106**: 563-573 [PMID: 21468064 DOI: 10.1038/ajg.2011.44]

12 **Viggiani MT**, Polimeno L, Di Leo A, Barone M. Phytoestrogens: Dietary Intake, Bioavailability, and Protective Mechanisms against Colorectal Neoproliferative Lesions. *Nutrients* 2019; **11** [PMID: 31344966 DOI: 10.3390/nu11081709]

13 **Křížová L**, Dadáková K, Kašparovská J, Kašparovský T. Isoflavones. *Molecules* 2019; **24** [PMID: 30893792 DOI: 10.3390/molecules24061076]

14 **Akhlaghi M**, Ghasemi Nasab M, Riasatian M, Sadeghi F. Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 2019; 1-15 [PMID: 31290343 DOI: 10.1080/10408398.2019.1635078]

15 **Yamagata K**. Soy Isoflavones Inhibit Endothelial Cell Dysfunction and Prevent Cardiovascular Disease. *J Cardiovasc Pharmacol* 2019; **74**: 201-209 [PMID: 31356541 DOI: 10.1097/FJC.0000000000000708]

16 **Chen M**, Rao Y, Zheng Y, Wei S, Li Y, Guo T, Yin P. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. *PLoS One* 2014; **9**: e89288 [PMID: 24586662 DOI: 10.1371/journal.pone.0089288]

17 **Yu Y**, Jing X, Li H, Zhao X, Wang D. Soy isoflavone consumption and colorectal cancer risk: a systematic review and meta-analysis. *Sci Rep* 2016; **6**: 25939 [PMID: 27170217 DOI: 10.1038/srep25939]

18 **Essawy AE**, Abdou HM, Ibrahim HM, Bouthahab NM. Soybean isoflavone ameliorates cognitive impairment, neuroinflammation, and amyloid β accumulation in a rat model of Alzheimer's disease. *Environ Sci Pollut Res Int* 2019; **26**: 26060-26070 [PMID: 31278647 DOI: 10.1007/s11356-019-05862-z]

19 **Braune A**, Maul R, Schebb NH, Kulling SE, Blaut M. The red clover isoflavone irilone is largely resistant to degradation by the human gut microbiota. *Mol Nutr Food Res* 2010; **54**: 929-938 [PMID: 19998384 DOI: 10.1002/mnfr.200900233]

20 **Sakai T**, Kogiso M. Soy isoflavones and immunity. *J Med Invest* 2008; **55**: 167-173 [PMID: 18797128 DOI: 10.2152/jmi.55.167]

21 **Dixon RA**, Sumner LW. Legume natural products: understanding and manipulating complex pathways for human and animal health. *Plant Physiol* 2003; **131**: 878-885 [PMID: 12644640 DOI: 10.1104/pp.102.017319]

22 **Cornwell T**, Cohick W, Raskin I. Dietary phytoestrogens and health. *Phytochemistry* 2004; **65**: 995-1016 [PMID: 15110680 DOI: 10.1016/j.phytochem.2004.03.005]

23 **Franke AA**, Lai JF, Halm BM. Absorption, distribution, metabolism, and excretion of isoflavonoids after soy intake. *Arch Biochem Biophys* 2014; **559**: 24-28 [PMID: 24946051 DOI: 10.1016/j.abb.2014.06.007]

24 **Izumi T**, Piskula MK, Osawa S, Obata A, Tobe K, Saito M, Kataoka S, Kubota Y, Kikuchi M. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. *J Nutr* 2000; **130**: 1695-1699 [PMID: 10867038 DOI: 10.1093/jn/130.7.1695]

25 **Shor D**, Sathyapalan T, Atkin SL, Thatcher NJ. Does equol production determine soy endocrine effects? *Eur J Nutr* 2012; **51**: 389-398 [PMID: 22366740 DOI: 10.1007/s00394-012-0331-7]

26 **Gu L**, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, Wilson ME, Badger TM. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. *J Nutr* 2006; **136**: 1215-1221 [PMID: 16614407 DOI: 10.1093/jn/136.5.1215]

27 **Vitale DC**, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. *Eur J Drug Metab Pharmacokinet* 2013; **38**: 15-25 [PMID: 23161396 DOI: 10.1007/s13318-012-0112-y]

28 **Tomás-Barberán FA**, Selma MV, Espín JC. Interactions of gut microbiota with dietary polyphenols and consequences to human health. *Curr Opin Clin Nutr Metab Care* 2016; **19**: 471-476 [PMID: 27490306 DOI: 10.1097/MCO.0000000000000314]

29 **Gaya P**, Peirotén Á, Medina M, Landete JM. Isoflavone metabolism by a collection of lactic acid bacteria and bifidobacteria with biotechnological interest. *Int J Food Sci Nutr* 2016; **67**: 117-124 [PMID: 26878882 DOI: 10.3109/09637486.2016.1144724]

30 **Gaya P**, Medina M, Sánchez-Jiménez A, Landete JM. Phytoestrogen Metabolism by Adult Human Gut Microbiota. *Molecules* 2016; **21** [PMID: 27517891 DOI: 10.3390/molecules21081034]

31 **Hur H**, Rafii F. Biotransformation of the isoflavonoids biochanin A, formononetin, and glycitein by Eubacterium limosum. *FEMS Microbiol Lett* 2000; **192**: 21-25 [PMID: 11040423 DOI: 10.1111/j.1574-6968.2000.tb09353.x]

32 **Raimondi S**, Roncaglia L, De Lucia M, Amaretti A, Leonardi A, Pagnoni UM, Rossi M. Bioconversion of soy isoflavones daidzin and daidzein by Bifidobacterium strains. *Appl Microbiol Biotechnol* 2009; **81**: 943-950 [PMID: 18820905 DOI: 10.1007/s00253-008-1719-4]

33 **Hur HG**, Lay JO Jr, Beger RD, Freeman JP, Rafii F. Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. *Arch Microbiol* 2000; **174**: 422-428 [PMID: 11195098 DOI: 10.1007/s002030000222]

34 **Hur HG**, Beger RD, Heinze TM, Lay JO Jr, Freeman JP, Dore J, Rafii F. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. *Arch Microbiol* 2002; **178**: 8-12 [PMID: 12070764 DOI: 10.1007/s00203-002-0414-6]

35 **Schoefer L**, Mohan R, Braune A, Birringer M, Blaut M. Anaerobic C-ring cleavage of genistein and daidzein by Eubacterium ramulus. *FEMS Microbiol Lett* 2002; **208**: 197-202 [PMID: 11959436 DOI: 10.1111/j.1574-6968.2002.tb11081.x]

36 **Yokoyama S**, Niwa T, Osawa T, Suzuki T. Characterization of an O-desmethylangolensin-producing bacterium isolated from human feces. *Arch Microbiol* 2010; **192**: 15-22 [PMID: 19904524 DOI: 10.1007/s00203-009-0524-5]

37 **Rowland I**, Faughnan M, Hoey L, Wähälä K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. *Br J Nutr* 2003; **89 Suppl 1**: S45-S58 [PMID: 12725656 DOI: 10.1079/BJN2002796]

38 **Tamura M**, Tsushida T, Shinohara K. Isolation of an isoflavone-metabolizing, Clostridium-like bacterium, strain TM-40, from human faeces. *Anaerobe* 2007; **13**: 32-35 [PMID: 17113326 DOI: 10.1016/j.anaerobe.2006.10.001]

39 **Wang XL**, Hur HG, Lee JH, Kim KT, Kim SI. Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. *Appl Environ Microbiol* 2005; **71**: 214-219 [PMID: 15640190 DOI: 10.1128/AEM.71.1.214-219.2005]

40 **Kim M**, Kim SI, Han J, Wang XL, Song DG, Kim SU. Stereospecific biotransformation of dihydrodaidzein into (3S)-equol by the human intestinal bacterium Eggerthella strain Julong 732. *Appl Environ Microbiol* 2009; **75**: 3062-3068 [PMID: 19304836 DOI: 10.1128/AEM.02058-08]

41 **Yokoyama S**, Suzuki T. Isolation and characterization of a novel equol-producing bacterium from human feces. *Biosci Biotechnol Biochem* 2008; **72**: 2660-2666 [PMID: 18838805 DOI: 10.1271/bbb.80329]

42 **Matthies A**, Blaut M, Braune A. Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. *Appl Environ Microbiol* 2009; **75**: 1740-1744 [PMID: 19139227 DOI: 10.1128/AEM.01795-08]

43 **Jin JS**, Kitahara M, Sakamoto M, Hattori M, Benno Y. Slackia equolifaciens sp. nov., a human intestinal bacterium capable of producing equol. *Int J Syst Evol Microbiol* 2010; **60**: 1721-1724 [PMID: 19734283 DOI: 10.1099/ijs.0.016774-0]

44 **Tsuji H**, Moriyama K, Nomoto K, Miyanaga N, Akaza H. Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS. *Arch Microbiol* 2010; **192**: 279-287 [PMID: 20237913 DOI: 10.1007/s00203-010-0546-z]

45 **Shimada Y**, Takahashi M, Miyazawa N, Ohtani T, Abiru Y, Uchiyama S, Hishigaki H. Identification of two novel reductases involved in equol biosynthesis in Lactococcus strain 20-92. *J Mol Microbiol Biotechnol* 2011; **21**: 160-172 [PMID: 22286043 DOI: 10.1159/000335049]

46 **van der Post S**, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, Johansson MEV, Hansson GC. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. *Gut* 2019; **68**: 2142-2151 [PMID: 30914450 DOI: 10.1136/gutjnl-2018-317571]

47 **Strugala V**, Dettmar PW, Pearson JP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. *Int J Clin Pract* 2008; **62**: 762-769 [PMID: 18194279 DOI: 10.1111/j.1742-1241.2007.01665.x]

48 **Salim SY**, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. *Inflamm Bowel Dis* 2011; **17**: 362-381 [PMID: 20725949 DOI: 10.1002/ibd.21403]

49 **Schmitz H**, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulzke JD. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. *Gastroenterology* 1999; **116**: 301-309 [PMID: 9922310 DOI: 10.1016/s0016-5085(99)70126-5]

50 **Olsen T**, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. *Cytokine* 2011; **56**: 633-640 [PMID: 21945121 DOI: 10.1016/j.cyto.2011.08.036]

51 **Ohman L**, Dahlén R, Isaksson S, Sjöling A, Wick MJ, Sjövall H, Van Oudenhove L, Simrén M, Strid H. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. *Inflamm Bowel Dis* 2013; **19**: 2433-2439 [PMID: 23966065 DOI: 10.1097/MIB.0b013e3182a563cb]

52 **Neurath MF**. Cytokines in inflammatory bowel disease. *Nat Rev Immunol* 2014; **14**: 329-342 [PMID: 24751956 DOI: 10.1038/nri3661]

53 **Michail S**, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, Leleiko N, Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with severe ulcerative colitis. *Inflamm Bowel Dis* 2012; **18**: 1799-1808 [PMID: 22170749 DOI: 10.1002/ibd.22860]

54 **Machiels K**, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. *Gut* 2014; **63**: 1275-1283 [PMID: 24021287 DOI: 10.1136/gutjnl-2013-304833]

55 **Varela E**, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2013; **38**: 151-161 [PMID: 23725320 DOI: 10.1111/apt.12365]

56 **Chen GL**, Zhang Y, Wang WY, Ji XL, Meng F, Xu PS, Yang NM, Ye FQ, Bo XC. Partners of patients with ulcerative colitis exhibit a biologically relevant dysbiosis in fecal microbial metacommunities. *World J Gastroenterol* 2017; **23**: 4624-4631 [PMID: 28740351 DOI: 10.3748/wjg.v23.i25.4624]

57 **Pascal V**, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, Vermeire S, Sokol H, Guarner F, Manichanh C. A microbial signature for Crohn's disease. *Gut* 2017; **66**: 813-822 [PMID: 28179361 DOI: 10.1136/gutjnl-2016-313235]

58 **Rajca S**, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. *Inflamm Bowel Dis* 2014; **20**: 978-986 [PMID: 24788220 DOI: 10.1097/MIB.0000000000000036]

59 **Sokol H**, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. *Gut* 2017; **66**: 1039-1048 [PMID: 26843508 DOI: 10.1136/gutjnl-2015-310746]

60 **Norman JM**, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, Stappenbeck TS, McGovern DP, Keshavarzian A, Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, Virgin HW. Disease-specific alterations in the enteric virome in inflammatory bowel disease. *Cell* 2015; **160**: 447-460 [PMID: 25619688 DOI: 10.1016/j.cell.2015.01.002]

61 **Sun M**, Wu W, Chen L, Yang W, Huang X, Ma C, Chen F, Xiao Y, Zhao Y, Ma C, Yao S, Carpio VH, Dann SM, Zhao Q, Liu Z, Cong Y. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. *Nat Commun* 2018; **9**: 3555 [PMID: 30177845 DOI: 10.1038/s41467-018-05901-2]

62 **Maslowski KM**, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 2009; **461**: 1282-1286 [PMID: 19865172 DOI: 10.1038/nature08530]

63 **Zhou L**, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, Chen X, Tang D, Xu L, Yin Y, Pan Y, Zhou Q, Zhou Y, Yu C. Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. *Inflamm Bowel Dis* 2018; **24**: 1926-1940 [PMID: 29796620 DOI: 10.1093/ibd/izy182]

64 **Laffin M**, Fedorak R, Zalasky A, Park H, Gill A, Agrawal A, Keshteli A, Hotte N, Madsen KL. A high-sugar diet rapidly enhances susceptibility to colitis via depletion of luminal short-chain fatty acids in mice. *Sci Rep* 2019; **9**: 12294 [PMID: 31444382 DOI: 10.1038/s41598-019-48749-2]

65 **Shen J**, Li N, Zhang X. Daidzein Ameliorates Dextran Sulfate Sodium-Induced Experimental Colitis in Mice by Regulating NF-κB Signaling. *J Environ Pathol Toxicol Oncol* 2019; **38**: 29-39 [PMID: 30806288 DOI: 10.1615/JEnvironPatholToxicolOncol.2018027531]

66 **Seo H**, Oh J, Hahn D, Kwon CS, Lee JS, Kim JS. Protective Effect of Glyceollins in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis. *J Med Food* 2017; **20**: 1055-1062 [PMID: 28956670 DOI: 10.1089/jmf.2017.3960]

67 **Głąbska D**, Guzek D, Grudzińska D, Lech G. Influence of dietary isoflavone intake on gastrointestinal symptoms in ulcerative colitis individuals in remission. *World J Gastroenterol* 2017; **23**: 5356-5363 [PMID: 28839435 DOI: 10.3748/wjg.v23.i29.5356]

68 **Skolmowska D**, Głąbska D, Guzek D, Lech G. Association between Dietary Isoflavone Intake and Ulcerative Colitis Symptoms in Polish Caucasian Individuals. *Nutrients* 2019; **11** [PMID: 31426486 DOI: 10.3390/nu11081936]

69 **Wiseman A**. Crohn's disease leading to bowel cancer may be avoided by consumption of soya isoflavones: adjunct-chemotherapy with oxaliplatin. *Med Hypotheses* 2006; **66**: 934-935 [PMID: 16431034 DOI: 10.1016/j.mehy.2005.11.038]

70 **Milán-Noris AK**, Gutiérrez-Uribe JA, Santacruz A, Serna-Saldívar SO, Martínez-Villaluenga C. Peptides and isoflavones in gastrointestinal digests contribute to the anti-inflammatory potential of cooked or germinated desi and kabuli chickpea (Cicer arietinum L.). *Food Chem* 2018; **268**: 66-76 [PMID: 30064805 DOI: 10.1016/j.foodchem.2018.06.068]

71 **Seibel J**, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Diel P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. *Eur J Nutr* 2009; **48**: 213-220 [PMID: 19234664 DOI: 10.1007/s00394-009-0004-3]

72 **Schreiber S**, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kühbacher T, Hämling J, Fölsch UR, Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. *Gut* 2002; **51**: 379-385 [PMID: 12171960 DOI: 10.1136/gut.51.3.379]

73 **Hämäläinen M**, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. *Mediators Inflamm* 2007; **2007**: 45673 [PMID: 18274639 DOI: 10.1155/2007/45673]

74 **Slomiany BL**, Slomiany A. Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin. *Inflammopharmacology* 2017; **25**: 415-429 [PMID: 28516374 DOI: 10.1007/s10787-017-0360-1]

75 **Sheibanie AF**, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. *J Immunol* 2007; **178**: 8138-8147 [PMID: 17548652 DOI: 10.4049/jimmunol.178.12.8138]

76 **Lejeune M**, Leung P, Beck PL, Chadee K. Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. *Am J Physiol Gastrointest Liver Physiol* 2010; **299**: G1097-G1105 [PMID: 20813914 DOI: 10.1152/ajpgi.00280.2010]

77 **Satsu H**, Hyun JS, Shin HS, Shimizu M. Suppressive effect of an isoflavone fraction on tumor necrosis factor-alpha-induced interleukin-8 production in human intestinal epithelial Caco-2 cells. *J Nutr Sci Vitaminol (Tokyo)* 2009; **55**: 442-446 [PMID: 19926933 DOI: 10.3177/jnsv.55.442]

78 **Wullaert A**. Role of NF-kappaB activation in intestinal immune homeostasis. *Int J Med Microbiol* 2010; **300**: 49-56 [PMID: 19781989 DOI: 10.1016/j.ijmm.2009.08.007]

79 **Mitchell JP**, Carmody RJ. NF-κB and the Transcriptional Control of Inflammation. *Int Rev Cell Mol Biol* 2018; **335**: 41-84 [PMID: 29305014 DOI: 10.1016/bs.ircmb.2017.07.007]

80 **Lawrence T**. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol* 2009; **1**: a001651 [PMID: 20457564 DOI: 10.1101/cshperspect.a001651]

81 **Spehlmann ME**, Eckmann L. Nuclear factor-kappa B in intestinal protection and destruction. *Curr Opin Gastroenterol* 2009; **25**: 92-99 [PMID: 19528876 DOI: 10.1097/MOG.0b013e328324f857]

82 **Nenci A**, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. *Nature* 2007; **446**: 557-561 [PMID: 17361131 DOI: 10.1038/nature05698]

83 **Kim SE**, Kawaguchi K, Hayashi H, Furusho K, Maruyama M. Remission Effects of Dietary Soybean Isoflavones on DSS-Induced Murine Colitis and an LPS-Activated Macrophage Cell Line. *Nutrients* 2019; **11** [PMID: 31362418 DOI: 10.3390/nu11081746]

84 **Lissner D**, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, May C, Schulzke JD, Siegmund B. Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD. *Inflamm Bowel Dis* 2015; **21**: 1297-1305 [PMID: 25901973 DOI: 10.1097/MIB.0000000000000384]

85 **Abron JD**, Singh NP, Price RL, Nagarkatti M, Nagarkatti PS, Singh UP. Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. *PLoS One* 2018; **13**: e0199631 [PMID: 30024891 DOI: 10.1371/journal.pone.0199631]

86 **Wang B**, Wu C. Dietary soy isoflavones alleviate dextran sulfate sodium-induced inflammation and oxidative stress in mice. *Exp Ther Med* 2017; **14**: 276-282 [PMID: 28672925 DOI: 10.3892/etm.2017.4469]

87 **Franchi L**, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. *Nat Immunol* 2012; **13**: 325-332 [PMID: 22430785 DOI: 10.1038/ni.2231]

88 **Bauer C**, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. *Gut* 2010; **59**: 1192-1199 [PMID: 20442201 DOI: 10.1136/gut.2009.197822]

89 **Tschopp J**, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* 2010; **10**: 210-215 [PMID: 20168318 DOI: 10.1038/nri2725]

90 **Al-Sadi R**, Ye D, Dokladny K, Ma TY. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. *J Immunol* 2008; **180**: 5653-5661 [PMID: 18390750 DOI: 10.4049/jimmunol.180.8.5653]

91 **Al-Sadi R**, Ye D, Said HM, Ma TY. IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. *Am J Pathol* 2010; **177**: 2310-2322 [PMID: 21048223 DOI: 10.2353/ajpath.2010.100371]

92 **Siegmund B**. Interleukin-18 in intestinal inflammation: friend and foe? *Immunity* 2010; **32**: 300-302 [PMID: 20346770 DOI: 10.1016/j.immuni.2010.03.010]

93 **Williams MA**, O'Callaghan A, Corr SC. IL-33 and IL-18 in Inflammatory Bowel Disease Etiology and Microbial Interactions. *Front Immunol* 2019; **10**: 1091 [PMID: 31139196 DOI: 10.3389/fimmu.2019.01091]

94 **Chen Y**, Le TH, Du Q, Zhao Z, Liu Y, Zou J, Hua W, Liu C, Zhu Y. Genistein protects against DSS-induced colitis by inhibiting NLRP3 inflammasome via TGR5-cAMP signaling. *Int Immunopharmacol* 2019; **71**: 144-154 [PMID: 30901677 DOI: 10.1016/j.intimp.2019.01.021]

95 **Hirota SA**, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, MacDonald JA, Beck PL. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. *Inflamm Bowel Dis* 2011; **17**: 1359-1372 [PMID: 20872834 DOI: 10.1002/ibd.21478]

96 **Zaki MH**, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. *Immunity* 2010; **32**: 379-391 [PMID: 20303296 DOI: 10.1016/j.immuni.2010.03.003]

97 **Lee JS**, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, Blumenschein WM, Judo M, Ayanoglu G, McClanahan TK, Li X, Cua DJ. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. *Immunity* 2015; **43**: 727-738 [PMID: 26431948 DOI: 10.1016/j.immuni.2015.09.003]

98 **Reynolds JM**, Martinez GJ, Nallaparaju KC, Chang SH, Wang YH, Dong C. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. *J Immunol* 2012; **189**: 4226-4230 [PMID: 23024280 DOI: 10.4049/jimmunol.1103014]

99 **Hohenberger M**, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. *J Dermatolog Treat* 2018; **29**: 13-18 [PMID: 28521565 DOI: 10.1080/09546634.2017.1329511]

100 **Maxwell JR**, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, Stevens E, Bigler J, Davis JA, Rottman JB, Budelsky AL, Symons A, Towne JE. Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. *Immunity* 2015; **43**: 739-750 [PMID: 26431947 DOI: 10.1016/j.immuni.2015.08.019]

101 **Kojima H**, Takeda Y, Muromoto R, Takahashi M, Hirao T, Takeuchi S, Jetten AM, Matsuda T. Isoflavones enhance interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ. *Toxicology* 2015; **329**: 32-39 [PMID: 25583575 DOI: 10.1016/j.tox.2015.01.007]

102 **Takahashi M**, Muromoto R, Kojima H, Takeuchi S, Kitai Y, Kashiwakura JI, Matsuda T. Biochanin A enhances RORγ activity through STAT3-mediated recruitment of NCOA1. *Biochem Biophys Res Commun* 2017; **489**: 503-508 [PMID: 28579428 DOI: 10.1016/j.bbrc.2017.05.181]

103 **Bunte K**, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. *Int J Mol Sci* 2019; **20** [PMID: 31295952 DOI: 10.3390/ijms20143394]

104 **Fujino S**, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 2003; **52**: 65-70 [PMID: 12477762 DOI: 10.1136/gut.52.1.65]

105 **van der Giessen J**, van der Woude CJ, Peppelenbosch MP, Fuhler GM. A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models. *Cells* 2019; **8** [PMID: 30893871 DOI: 10.3390/cells8030261]

106 **Braniste V**, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. *J Physiol* 2009; **587**: 3317-3328 [PMID: 19433574 DOI: 10.1113/jphysiol.2009.169300]

107 **Moussa L**, Bézirard V, Salvador-Cartier C, Bacquié V, Lencina C, Lévêque M, Braniste V, Ménard S, Théodorou V, Houdeau E. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease. *PLoS One* 2012; **7**: e49547 [PMID: 23166707 DOI: 10.1371/journal.pone.0049547]

108 **Vázquez L**, Flórez AB, Guadamuro L, Mayo B. Effect of Soy Isoflavones on Growth of Representative Bacterial Species from the Human Gut. *Nutrients* 2017; **9** [PMID: 28698467 DOI: 10.3390/nu9070727]

109 **Pagnini C**, Corleto VD, Martorelli M, Lanini C, D'Ambra G, Di Giulio E, Delle Fave G. Mucosal adhesion and anti-inflammatory effects of *Lactobacillus rhamnosus* GG in the human colonic mucosa: A proof-of-concept study. *World J Gastroenterol* 2018; **24**: 4652-4662 [PMID: 30416313 DOI: 10.3748/wjg.v24.i41.4652]

110 **Martín R**, Chamignon C, Mhedbi-Hajri N, Chain F, Derrien M, Escribano-Vázquez U, Garault P, Cotillard A, Pham HP, Chervaux C, Bermúdez-Humarán LG, Smokvina T, Langella P. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. *Sci Rep* 2019; **9**: 5398 [PMID: 30931953 DOI: 10.1038/s41598-019-41738-5]

111 **Luo Q**, Cheng D, Huang C, Li Y, Lao C, Xia Y, Liu W, Gong X, Hu D, Li B, He X, Chen Z. Improvement of Colonic Immune Function with Soy Isoflavones in High-Fat Diet-Induced Obese Rats. *Molecules* 2019; **24** [PMID: 30909396 DOI: 10.3390/molecules24061139]

112 **Guadamuro L**, Dohrmann AB, Tebbe CC, Mayo B, Delgado S. Bacterial communities and metabolic activity of faecal cultures from equol producer and non-producer menopausal women under treatment with soy isoflavones. *BMC Microbiol* 2017; **17**: 93 [PMID: 28415978 DOI: 10.1186/s12866-017-1001-y]

113 **Ohfuji S**, Fukushima W, Watanabe K, Sasaki S, Yamagami H, Nagahori M, Watanabe M, Hirota Y; Japanese Case-Control Study Group for Ulcerative Colitis. Pre-illness isoflavone consumption and disease risk of ulcerative colitis: a multicenter case-control study in Japan. *PLoS One* 2014; **9**: e110270 [PMID: 25314032 DOI: 10.1371/journal.pone.0110270]

114 **Seibel J**, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Degen GH, Diel P. In utero and postnatal exposure to a phytoestrogen-enriched diet increases parameters of acute inflammation in a rat model of TNBS-induced colitis. *Arch Toxicol* 2008; **82**: 941-950 [PMID: 18504553 DOI: 10.1007/s00204-008-0309-7]

115 **Khalili H**, Higuchi LM, Ananthakrishnan AN, Manson JE, Feskanich D, Richter JM, Fuchs CS, Chan AT. Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. *Gastroenterology* 2012; **143**: 1199-1206 [PMID: 22841783 DOI: 10.1053/j.gastro.2012.07.096]

116 **Ortizo R**, Lee SY, Nguyen ET, Jamal MM, Bechtold MM, Nguyen DL. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. *Eur J Gastroenterol Hepatol* 2017; **29**: 1064-1070 [PMID: 28542115 DOI: 10.1097/MEG.0000000000000915]

117 **Ko KP**. Isoflavones: chemistry, analysis, functions and effects on health and cancer. *Asian Pac J Cancer Prev* 2014; **15**: 7001-7010 [PMID: 25227781 DOI: 10.7314/apjcp.2014.15.17.7001]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 2, 2020

**First decision:** February 19, 2020

**Article in press:**

**Specialty type:** Medicine, Research and Experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P- Reviewer:** Chiu KW, Slomiany BL, Tomizawa M **S- Editor:** Dou Y **L- Editor:** Wang TQ **E- Editor:**

**Figure Legends**



**Figure 1 The metabolic process of isoflavones[**13,27,29,31-36,38-45,117**].**

****

**Figure 2 The effects of isoflavones on inflammatory bowel disease.** SCFA: Short-chain fatty acids; STAT1: Signal transducer and activator of transcription 1; COX2: NO: Nitric oxide; iNOS: Inducible nitric oxide synthase; PGE2: Prostaglandin E2; NF-κB: Nuclear factor-κB; NLRP3: NOD-, LRR-, and pyrin domain-containing protein 3; TNF-α: Tumor necrosis factor α; IL-8: Interleukin-8.